---
title: Detect colonic phosphorylated alpha synuclein
nct_id: NCT07217054
status: RECRUITING
sponsor: CND Life Sciences
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07217054"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07217054"
last_fetched: "2026-05-10T14:05:00.116Z"
source: "Parkinson's Pathways (curated)"
---
# Detect colonic phosphorylated alpha synuclein

**Goal (in five words):** Detect colonic phosphorylated alpha synuclein

**Official Title:** Detection of Phosphorylated Alpha-Synuclein in Colonic Tissue Biopsy During Routine Colonoscopy

**Trial ID:** [NCT07217054](https://clinicaltrials.gov/study/NCT07217054)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** CND Life Sciences
- **Target Enrollment:** 40 participants
- **Start Date:** 2025-11-04
- **Completion Date:** 2028-10
- **Conditions:** PARKINSON DISEASE (Disorder), Parkinson, Parkinson s Disease, Parkinson Disease

## Summary For Families

The goal is to see whether a pathological form of alpha-synuclein, called phosphorylated alpha-synuclein, can be detected in colon biopsy tissue and whether that finding could help confirm Parkinson's or flag higher risk in people with REM sleep behavior disorder. The approach is to collect small biopsy samples during a routine colonoscopy and test the tissue for phosphorylated alpha-synuclein, this is an observational biomarker study and it does not change Parkinson's medications like levodopa. If phosphorylated alpha-synuclein is present in colon tissue, it could serve as a supportive tissue biomarker for diagnosis or early detection. The study is enrolling adults 40 to 99 who already agree to have a routine colonoscopy and who have clinically confirmed Parkinson's disease or clinically confirmed RBD without PD, DLB, or MSA; people on anticoagulants, with active GI illness, recent abdominal surgery, active cancer treatment, pregnancy, or significant cognitive impairment are excluded, though aspirin or Plavix alone may be allowed.

## Eligibility

- **Minimum age:** 40 Years
- **Maximum age:** 99 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

1. Relatively healthy men and women ≥40-99 years of age
2. Patients with a diagnosis of

   1. Clinically confirmed PD or
   2. Clinically confirmed RBD with no diagnosis of PD, DLB or MSA
3. Patients must have agreed to undergo a routine colonoscopy as part of their screening or surveillance for colon cancer or for diagnostic purposes for the exclusion of other GI diseases

Exclusion Criteria:

1. Use of anticoagulants (Plavix or aspirin alone is allowed)
2. Under active treatment for colon cancer; 30-day post anti-cancer treatment allowed
3. Current, ongoing gastrointestinal illness
4. Recent intrabdominal surgery
5. Pregnant or planning to become pregnant before the scheduled colonoscopy
6. Significant cognitive impairment, as determined by study investigators
```

## Locations (1)

- Digestive Disease Associates, Branford, Connecticut, United States _(41.2795, -72.8151)_
  - Christina Wagner — (CONTACT) — 203-481-0315 — cwagner@ddabranford.com
  - Daniel J Zanchetti, MD — (PRINCIPAL_INVESTIGATOR)

## Central Contacts

- Christina Wagner — (CONTACT) — 203-481-0315 — cwagner@ddabranford.com

---

*Canonical: https://parkinsonspathways.com/trial/NCT07217054*  
*HTML version: https://parkinsonspathways.com/trial/NCT07217054*  
*Source data: https://clinicaltrials.gov/study/NCT07217054*